Comparative safety of Janus kinase inhibitors and tumor necrosis factor inhibitors in patients undergoing treatment for rheumatoid arthritis-Reference-Cited by-同舟云学术

Comparative safety of Janus kinase inhibitors and tumor necrosis factor inhibitors in patients undergoing treatment for rheumatoid arthritis

Published:2022-08-03 Issue:11 Volume:25 Page:1254-1262
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J of Rheum Dis

Author:

Fang Yao‐Fan¹^ORCID,Liu Jia‐Rou²,Chang Shu‐Hao²,Kuo Chang‐Fu¹,See Lai‐Chu¹²³

Affiliation:

1. Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine Chang Gung Memorial Hospital at Linkou Taoyuan City Taiwan

2. Department of Public Health, College of Medicine Chang Gung University Taoyuan City Taiwan

3. Biostatistics Core Laboratory, Molecular Medicine Research Center Chang Gung University Taoyuan City Taiwan

Publisher

Wiley

Subject

Rheumatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1756-185X.14414

Reference29 articles.

1. Rheumatoid arthritis

2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

3. U.S. Food & Drug Administration.Janus Kinase (JAK) inhibitors: drug safety communication ‐ FDA requires warnings about increased risk of serious heart‐related events cancer blood clots and death.2021.https://www.fda.gov/safety/medical‐product‐safety‐information/janus‐kinase‐jak‐inhibitors‐drug‐safety‐communication‐fda‐requires‐warnings‐about‐increased‐risk. Accessed September 01 2021.

Taiwan’s National Health Insurance Research Database: past and future

5. The impact of introducing biologics to patients with rheumatoid arthritis in Taiwan: a population-based trend study

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis;RMD Open;2024-04

2. Impact of age and cardiovascular risk factors on the incidence of adverse events in patients with rheumatoid arthritis treated with Janus Kinase inhibitors: data from a real-life multicentric cohort;Clinical and Experimental Medicine;2024-03-30

3. Hunting uncertainties: JAK inhibitors and cancer risk;International Journal of Rheumatic Diseases;2024-02

4. Disproportional signal of pericarditis with biological diseasemodifying antirheumatic drugs (bDMARDs) in patients with ankylosing spondylitis: a disproportionality analysis in the FAERS database;Frontiers in Pharmacology;2024-01-25

5. Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study;The Lancet Regional Health - Western Pacific;2024-01